

[Click here to view linked References](#)

# **Potential neoplastic evolution of Vero cells: *in vivo* and *in vitro* characterization**

N.A. Andreani<sup>a</sup>\*, S. Renzi<sup>a</sup>, G. Piovani<sup>b</sup>, P. Ajmone Marsan<sup>c</sup>, L. Bomba<sup>c</sup>, R. Villa<sup>a\*</sup>, M. Ferrari<sup>a</sup>, S. Dotti<sup>a</sup>

<sup>a</sup>Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Via Bianchi 9, 25124 Brescia. <sup>b</sup>Department of Molecular and Translational Medicine, University of Brescia, V.le Europa 11, 25123 Brescia, Italy. <sup>c</sup>Università Cattolica del Sacro Cuore di Piacenza, Italy.

\*: These authors equally contributed to the study

\*Corresponding Author: riccardo.villa@izsler.it. Tel.: +390302290248 fax: +390302290392.

ORCID:

N.A. Andreani 0000-0003-0330-9874

S. Renzi 0000-0001-5863-2105

G. Piovani 0000-0003-0001-6435

P. Ajmone Marsan 0000-0003-3165-4579

L. Bomba 0000-0002-6290-8984

R. Villa 0000-0001-8385-800X

M. Ferrari 0000-0001-7949-651X

S. Dotti 0000-0002-2303-2027

## **Acknowledgements**

The authors thank Dr. Roberta Trainini, Dr. Chiara Tontini for technical assistance and Dr. Daniela Gelmetti and Dr. Lucia Gibelli for histological investigations.

**The study has been supported by a grant from the Regione Lombardia (Project Reg. Lomb. Cell 2008).**

26   **Abstract**

27   Vero cell lines are extensively employed in viral vaccine manufacturing. Similarly to all established  
28   cells, mutations can occur during Vero cells *in vitro* amplification which can result in adverse  
29   features compromising their biological safety.

30   To evaluate the potential neoplastic evolution of these cells, *in vitro* transformation test, gene  
31   expression analysis and karyotyping were compared among low- (127 and 139 passages) and high-  
32   passage (passage 194) cell lines, as well as Transformed Colonies (TCs). *In vivo* tumorigenicity was  
33   also tested to confirm preliminary *in vitro* data obtained for low passage lines and TCs. Moreover,  
34   Vero cells cultivated in foetal bovine serum-free medium and derived from TCs were analysed to  
35   investigate the influence of cultivation methods on tumorigenic evolution.

36   Low-passage Vero developed TCs in soft agar, without showing any tumorigenic evolution when  
37   inoculated in the animal model. Karyotyping showed a hypo-diploid modal chromosome number  
38   and rearrangements with no difference among Vero cell line passages and TCs. These abnormalities  
39   were reported also in serum-free cultivated Vero. Gene expression revealed that high-passage Vero  
40   cells had several under-expressed and a few over-expressed genes compared to low-passage ones.  
41   Gene ontology revealed no significant enrichment of pathways related to oncogenic risk.

42   These findings suggest that *in vitro* high passage, and not culture conditions, induces Vero  
43   transformation correlated to karyotype and gene expression alterations. These data, together with  
44   previous investigations reporting tumour induction in high-passage Vero cells, suggest the use of  
45   low-passage Vero cells or cell lines other than Vero to increase the safety of vaccine manufacturing.

46

47   **Keywords:** Vero cells, Transformation, *In vitro* test, Tumorigenicity, *In vivo* test, RNAseq.

48

## 49    **Introduction**

50    A wide variety of cell cultures are used as the substrate for the production of relevant biologicals  
51    such as viral vaccines with human and veterinary applications. Cell substrates for this specific aim  
52    can be primary, diploid, stem or continuous cell lines, derived from physiologically normal,  
53    abnormal or malignant tissues (Aubrit et al. 2015). Normal tissue-derived cells can anyway undergo  
54    several modifications during *in vitro* cultivation, resulting in the appearance of novel biochemical,  
55    biological and genetic characteristics that differ from primary or diploid cells. In particular, these  
56    cells could acquire genetic instability as well as tumorigenic properties with increasing passages  
57    (Sheets 2000; Aubrit et al. 2015). The WHO Expert Committee reported tumorigenicity of a cell  
58    line as the ability to induce tumour formation after injection in immunocompromised animals  
59    (WHO Technical report Series, No 978, 2013, Annex 3). In fact, the utilization of tumorigenic cell  
60    lines might be involved in the transmission of tumour allografts, transforming proteins or  
61    oncogenic agents inducing tumour initiation in the recipient (Aubrit et al. 2015).

62    In this respect, it is mandatory for vaccine production and safety assessment a fine characterization  
63    of the cell substrate in each phase of its manipulation. European Pharmacopeia recommends a panel  
64    of tests to assess cell substrate safety (Cell substrates for the production of vaccines for human use.  
65    European Pharmacopoeia Ed. 08 Chapter 5.2.3), as the use of tumorigenic cell lines for vaccine  
66    production is forbidden. Among these, to avoid potential risks related to cell transformation and  
67    tumorigenicity, both *in vitro* and *in vivo* tests are required to evaluate cell growth characteristics and  
68    reveal the onset of tumorigenic properties.

69    Vero is a well-known immortalized cell line, used as substrate for virus isolation and production of  
70    vaccines, i.e. *Poliovirus*, rabies virus (Montagnon 1989), influenza (Govorkova et al. 1996; Barrett  
71    et al. 2011, 2013), and Japanese encephalitis virus (Shuller et al. 2011), due to its susceptibility to a  
72    wide range of viruses (Rhim et al. 1969; Teferedegne et al. 2014). Vero cells were originally  
73    collected from the kidney of a normal adult African Green Monkey (*Cercopithecus aethiops*)  
74    kidney (AGMK; Yasumura and Kawakita 1963) and immortalized through a spontaneous, unknown

75 process (Swanson et al. 1988; Manohar et al. 2008). On the basis of CBER (Centre for Biologics  
76 Evaluation and Research) classification, Vero cells are included in neoplastic substrate category 3,  
77 in which spontaneously immortalized non-human primate cells are grouped (US FDA 2001).

78 Previous studies demonstrated that low-passage (p140) Vero cells are not able to form tumours *in*  
79 *vivo*, neither show the formation of extraneous agent in the host, while progressively growing  
80 nodules and lung and lymph node metastases were observed at higher passages (> p200; Manohar et  
81 al. 2008). Levenbook and colleagues demonstrated nodule formation in the totality of mice  
82 inoculated with Vero cells at passages higher than 232 (Levenbook et al. 1984), while no tumour  
83 formation was observed in nude mice inoculated with p156 Vero cells by Swanson et al. (1988). On  
84 the other hand, *in vitro* assay gave rise to not completely clear results, since Vero cells from p127 to  
85 p140 and from p162 to p265 formed colonies in soft agar (Petricciani et al. 1987).

86 These findings, taken together, indicated Vero cells as a suitable and safe biological resource for  
87 vaccine production only at low passages, but data are still controversial due to the lack of  
88 consistence between *in vitro* and *in vivo* tests. Moreover, the mechanism inducing neoplastic  
89 transformation in Vero cells remains an elusive point (Manohar et al. 2008).

90 The application of serum-free media has become established recently to cultivate cells without the  
91 addition of animal derivatives. Despite the positive aspects of serum addition to media (related to  
92 cell attachment and growth), the employment of serum in cell cultures has some disadvantages  
93 (Chen and Chen 2009), such as the uncertainty of the composition and the putative contamination  
94 with adventitious agents. Previous studies demonstrated the ability of Vero cells to grow in animal  
95 serum-free medium while maintaining their permissiveness to viral propagation (Frazatti-Gallina et  
96 al. 2004; Chen et al. 2011), suggesting the applicability of serum-free medium in vaccine  
97 manufacturing. To date no data is available on the correlation between culture conditions and  
98 neoplastic phenotype evolution in Vero cells.

99 The present study aimed to characterize *in vitro* amplified Vero cells at low and high passages.  
100 Additionally, normal and serum-free growth conditions were tested. Transformation ability of low

101 and high-passage cells was investigated by soft agar transformation assay. Moreover, p127 and  
102 p139 Vero cells were tested for tumorigenic phenotype by nude mice inoculation. With the aim of  
103 shedding light on the mechanisms inducing the neoplastic phenotype, cell lines were analysed  
104 through karyotyping and gene expression study. To study the behaviour of the *in vitro* transforming  
105 samples, six of the soft agar transforming colonies were amplified, evaluated by inoculation in soft  
106 agar and in nude mice and examined by karyotyping.

## 107 **Material and methods**

### 108 **Cell culture**

109 Vero cells (African green monkey kidney, IZSLER Cell Bank code BS CL 86) were received from  
110 ATCC (American Type Culture Collection) at p124 and grown in MEM culture medium (Eagle's  
111 Minimum Essential Medium in Earle's BSS) enriched with 10% Fetal Bovine Serum (FBS) and 2  
112 mM L-glutamine. From p127 they were grown concurrently in serum-free medium. XerumFree™  
113 XF205 Medium Supplement (TNC BIO, Eindhoven, Holland) was gradually added to cultural  
114 medium in substitution of FBS, starting from 50% XerumFree-supplemented medium/50% FBS-  
115 supplemented medium, according to manufacturer instructions. Cultures adapted to serum-free  
116 conditions were amplified in medium supplemented with Epidermal Growth Factor (EGF; 12.5  
117 µg/L, Sigma Aldrich, Milano, Italy) and insulin (1.25 mg/L, Sigma Aldrich). At each passage, cells  
118 were mechanically scraped and incubated in a mixture of 75% fresh medium and 25% conditioned  
119 medium, collected during the previous passage.

120 HEp-2 (Human larynx epidermal carcinoma, BSTCL 23) and MRC-5 cells (Human foetal lung,  
121 BSCL 68), were grown in MEM culture medium supplemented with 10% FBS and 2 mM L-  
122 glutamine. These cell lines were used respectively as positive and negative control in tumorigenicity  
123 and transformation assays.

124 A primary cell culture (passage 3) of a normal adult African Green Monkey Kidney (AGMK,  
125 *Cercopithecus aethiops*) was kindly provided by Dr. Brandini (Novartis Vaccines Italia, Siena,  
126 Italy) and grown in MEM culture medium enriched with 10% FBS, 1% Penicillin/Streptomycin and

127 2 mM L-glutamine. This cell line was used as reference in the *in vitro* transformation assay and  
128 karyotype analyses. Figure S1 summarizes cell lines used in each investigation reported hereunder.

#### 129 ***In vitro* transformation assay**

130 Vero (from p127 to p139 and p194), as well as AGMK, MRC-5 and Hep2 negative and positive  
131 control cells were assayed for *in vitro* transformation according to European Pharmacopoeia  
132 guidelines, by seeding cell lines in semi-solid agar medium (Macpherson and Montagnier 1964).  
133 Briefly, 1% agar noble was mixed with 50% of 2X MEM, supplemented with 20% FBS and  
134 stratified into 6-well plates (3 ml/well).  $10^5$  p139 Vero cells were diluted in 1 mL of 20% FBS-  
135 MEM (v/v) and 0.6% noble agar and gently layered onto solidified agar. Plates were incubated at  
136 37°C in 5% CO<sub>2</sub> for 3 weeks and inspected daily to detect TCs. To assess serum free-culturing  
137 conditions, the same cells were grown in medium supplemented with Xerum-free instead of FBS  
138 before *in vitro* transformation assay.

#### 139 **Isolation and amplification of Vero transformed colonies (TCs)**

140 Six TCs developed in the soft agar assay, originated from p139 Vero, were collected under sterile  
141 conditions and disaggregated mechanically. Cells derived from each single colony were inoculated  
142 in a well of a 48-well plate and grown in the previously described medium. When cells reached  
143 80%-confluence, they were serially amplified and characterized as described below.

#### 144 ***In vivo* tumorigenicity test**

145 The choice of the animal model for *in vivo* tests was based on the results of published investigations  
146 reporting the validity of experimental data produced on adult nude mice (Swanson et al., 1988;  
147 Zhang et al., 2004; Manohar et al. 2008) and on European Pharmacopoeia guidelines.

148 Vero cell samples (at p127 and p139, serum-added and serum-free cultured), as well as the six TC  
149 samples and positive (Hep-2) and negative (MRC-5 and AGMK) controls were inoculated into nude  
150 mice to verify tumorigenic potential *in vivo*. According to Directive 2010/63/EU and the 3Rs  
151 principle stated by Russell and Burch (1959), the high passage (p194) Vero cells were not included

152 in the *in vivo* test, as they were previously demonstrated to induce tumour formation in nude mice  
153 (Petricciani et al. 1987).

154 *In vivo* tests were performed as described in European Pharmacopoeia guidelines in 20-day-old  
155 male athymic mice (Nu/Nu genotype), received from Harlan Laboratories (Milan, Italy) in  
156 accordance with local animal welfare guidelines. Ten mice per treatment (Vero p127, Vero p139,  
157 the six TCs and positive and negative controls) were used. They were sub-divided into groups of  
158 five mice/cage, maintained at the IZSLER Division of Laboratory Animal on sterile bedding and  
159 given water and feed *ad libitum*. Animals were injected subcutaneously into the abdominal wall  
160 with a  $10^7$ -cell suspension in 0.2 mL of volume. Five mice were sacrificed by CO<sub>2</sub> inhalation three  
161 weeks after the treatment, while the others were inspected daily for 12 weeks. The regional lymph  
162 nodes, lung, brain, spleen, kidney, liver and the injection site were examined post-mortem to detect  
163 tumours, for histological examination and haematoxylin-eosin staining.

#### 164 **Cell karyotype evaluation**

165 Cytogenetic studies were performed on chromosomes derived from AGMK (control cell line) and  
166 Vero cells collected at different passages (from p127 to p139 and p194), cultured both with FBS  
167 and Xerum-free supplement. Cell lines derived from the six Vero-transformed colonies (TCs) were  
168 also analysed.

169 Chromosome preparations were obtained according to standard cytogenetic techniques. Cytogenetic  
170 analysis was performed using Quinacrine staining (0.05 mg/mL Quinacrine Mustard  
171 Dihydrochloride C<sub>23</sub>H<sub>28</sub>Cl<sub>3</sub>N<sub>3</sub>O 2HCl, Sigma-Aldrich, Milan, Italy) and analysing an average of  
172 twenty metaphases per sample. Karyotypes were compared with the normal primate karyotype  
173 (Finaz et al. 1976).

#### 174 **Gene expression analysis**

175 Differences in gene expression were investigated comparing low (p127, p134) and high (p194)  
176 culture passages of Vero cells cultured in the presence of FBS. Total RNA was extracted from  $10^7$   
177 cells using RNeasy Mini Kit with a QIAcube platform (Qiagen, Milan, Italy) according to the

178 instructions of the manufacturer. RNA quantity and quality were assessed by a 2200 TapeStation  
179 RNA Screen Tape device (Agilent, Santa Clara, CA, USA) and a ND-1000 spectrophotometer  
180 (NanoDrop, Thermo Scientific, Wilmington, DE), respectively.

181 Libraries were prepared with the TruseqRNA sample prep kit (Illumina, Inc. San Diego, CA)  
182 following manufacturer's protocol and their evaluation was made with a Tape Station 2200.  
183 Indexed libraries were quantified by Picogreen (Life Technologies, Monza, Italy) and then  
184 normalized to 10 nM for cluster generation on a Hiseq2000 (Illumina). Equimolar amounts of each  
185 library were mixed before NaOH denaturation and pooled samples were run in a total of two lanes  
186 of a Hiseq Flowcell (Illumina).

187 The Truseq PE cluster kit v3 was used to generate clusters on the grafted Flowcell and the  
188 hybridized libraries were sequenced on a Hiseq2000 with a 100 cycles of paired-end sequencing  
189 module using the Truseq SBS kit v3.

#### 190 **RNA-seq data analysis**

191 Standard trimming was performed using Trimmomatic software, to remove the adapters and check  
192 the quality of the reads (Bolger et al. 2014). Only RNA-seq reads that passed the trimming  
193 procedures were mapped to "Vervet Monkey" reference genome (Green monkey chlSab1, Jun 2013,  
194 Chlorocebus\_sabeus 1.0/chlSab1, Vervet Genomics Consortium GCA\_000409795.1) using Star  
195 aligner, with default parameters (Dobin et al. 2013). Alignments were sorted using Samtools  
196 software (Li et al. 2009). For each sample, the number of reads mapped into each specific gene was  
197 calculated using htseq-count program (Anders et al. 2015).

198 Differential expression among pairwise comparisons was analysed using the edgeR package  
199 (Robinson et al. 2010). EdgeR permits to estimate a common dispersion to the theses to be  
200 compared even in the absence of biological replicates (Bioconductor). Hence, edgeR permits the  
201 statistical analysis of data lacking replicates and conduct exact tests of significance for the negative  
202 binomial distribution in pairwise comparisons.



203 A multiple testing correction was applied to determine the false discovery rate (FDR; Reiner et al.  
204 2003). Genes with a FDR-adjusted p-value (q-value) of  $\leq 0.05$  and log fold change lower than -3  
205 and higher than 3 were considered to be Differential Expressed Genes (DEGs). Groups of genes  
206 significant in a single or in multiple comparisons have been graphically represented by Venn  
207 analysis.

## 208 **Ontology and clustering of differentially expressed genes**

209 Clustering of gene expression levels in each sample and differential gene expression in pairwise  
210 comparisons were also produced for DEGs identified by contrasting p127, p134 and p194 Vero  
211 cells and visualized as heatmaps and dendrograms. Dendrograms were generated with Euclidian  
212 distance as measure of dissimilarities and complete linkage as agglomeration method using *dist* and  
213 *hclust* function implemented in R packages. Gene Ontology (GO) analysis was carried out using  
214 g:Profiler, a web server for functional interpretation of gene list (Reimand et al. 2016).

## 215 **Results**

### 216 ***In vitro* transformation assay**

217 Foci formation took place for HEp-2 cells, used as positive control (Fig. 1B), and all Vero cell lines.  
218 Foci appeared 7 days after the inoculum and gradually increased in both number and size. An  
219 example is reported in figure 1A, reporting cells at passage 130. TCs isolated from p139 Vero cells  
220 and assayed for *in vitro* transformation also produced foci of transformed colonies.

221 No significant difference was observed among samples at different passages and culture conditions.  
222 Results are summarized in Table 1 and Figure S1.

223 Conversely, no transformed colony was observed in the negative control MRC-5 and AGMK  
224 cultures, where cells remained unaltered during all the observation period (Fig. 1C).

### 225 ***In vivo* tumorigenic test**

226 Both inoculation of MRC-5 cells (negative control) and Vero cells (at passage p127, p136 and TCs  
227 in both culture conditions) did not induce tumour formation during the observation period. Results  
228 of the *in vivo* tumorigenicity are summarized in Table 1 and Figure S1. No macroscopic lesion and

229 inflammatory process were observed in treated animals and the inoculum was re-absorbed  
230 completely within few days (an average of seven days). The necropsy detected no tumour formation  
231 at the site of inoculation neither in other organs and tissues, with no macroscopic lesions. These  
232 observations were confirmed by histological examination. Mice showed hyperkeratosis, moderate  
233 lymphoplasmacellular enteritis and dismicrobism bowel, pulmonary bleeding and rare intracranial  
234 bleeding, but neither microscopic anomalies nor neoplastic cells were observed in all tissues  
235 examined.

236 In contrast, tumours were detected in all mice receiving HEp-2 cells. In particular, nodules were  
237 observed at the inoculation site about 10 days after the injection. They appeared smooth, uniform  
238 and globular (10 mm Ø); later they developed a multi-globular shape and increased in size (20 mm  
239 Ø). At about 30 days after the injection, the mice were sacrificed to avoid animal pain and suffering.  
240 At necropsy, no other macroscopic alterations in organs and tissues were detected. The histological  
241 examination of the mice injected with HEp-2 cells showed the presence of polygonal cells in  
242 subcutaneous and dermal tissues; the nuclei of such cells were irregular in shape, with evident  
243 nucleoli (atypical mitosis); moreover, neoplastic cells were observed in the vessels. These  
244 alterations were restricted to the inoculum site in all the animals and no metastases were found.

#### 245 **Cell karyotype evaluation**

246 AGMK cell line karyotype showed normal diploid number of chromosomes ( $2n = 60$ ; Finelli et al.  
247 1999). All analysed Vero samples at different passages showed hypodiploid chromosome count.  
248 The modal chromosome number was 56 with a range from 54 to 58 (as reported in the ATCC site)  
249 occurring in 75% of cells. In most cells, over 50% of the chromosomes in each metaphase were  
250 structurally altered marker chromosomes. The rate of cells with higher ploidies was 2%, while  
251 different chromosomes were present in single copy in different cell cultures. The chromosomal  
252 asset of Vero cell lines resulted stable without significant differences between the assayed *in vitro*  
253 passages (Figure 2). The chromosome analysis of TC colonies, originated from p139, and of serum-

254 free cultivated Vero cells, showed the same abnormal karyotype. Results of karyotyping are  
255 summarized in Table 1.

## 256 **Gene expression analysis**

257 Gene expression data revealed that some of the 20.126 unique genes identified, were expressed only  
258 in one of the passages analysed. Specifically, a total of 89 (4.42%), 175 (8.70%) and 220 (10.93%)  
259 genes were found exclusively expressed in p127, p134 and p194 respectively, and not elsewhere.

260 Comparing the three Vero passages, 350 genes were found differentially expressed in one or more  
261 pairwise comparisons. Among these, 41 were DEGs between p127 and p134 Vero cells, and 309  
262 between these two lines and p194 Vero. No gene was differentially expressed in all comparisons  
263 (Fig. 3).

264 The logarithm of the normalized expression level of the 309 genes differentially expressed  
265 comparing the high passage (p194 Vero) to low passages (p127 Vero and p134 Vero) are shown in  
266 Figure 4. DEG analysis indicated that p127 Vero and p134 Vero have very similar gene expression  
267 (lane 1). Additionally, the comparison between p127, p134 and p194 Vero cells (lane 2 and 3)  
268 indicates that p194 Vero cells have a larger number of down-regulated genes compared to up-  
269 regulated ones as 231 and 228 genes out of 309 were under-expressed in p194 Vero compared to  
270 p134 and p127 cells, respectively.

271 Table S1 reports values of log Fold-change of expression in pairwise comparisons.

## 272 **Function of differentially expressed genes**

273 The main biological processes identified by GO analysis were relative to response to corticotropin-  
274 releasing hormone, response to growth factor and sprouting angiogenesis. GO analysis showed no  
275 significant enrichment of DEG in metabolic pathways relative to oncogenesis.

## 276 **Discussion**

277 Vero cells are commonly used in human and veterinary vaccine production and their safety has  
278 been widely investigated. A particular concern is related to the tumorigenicity of this cellular  
279 substrate, since a potential tumorigenic evolution of *in vitro*-maintained Vero cells (passages from

131 to 227) has been reported by many authors (Van Steenis and van Wezel 1981; Contreras et al. 1985; Furesz et al. 1989; Zhang et al. 2001). Indeed, data are still controversial because other studies showed that these cells did not acquire tumorigenic features at passages higher than 140 (Johnson et al. 1981; Levenbook et al. 1984; Swanson et al. 1988).

As mentioned above, transforming phenotype (defined as the ability of cells to proliferate without undergo the common proliferative controls; Hoff et al. 2004) and tumorigenicity (the ability of cultured cells to originate progressively growing tumours) can be respectively evaluated *in vitro* (soft agar assay) and *in vivo* (inoculation in nude mouse).

Among *in vitro* tests, the soft-agar assay is widely applied, as it is an easy and low-cost test recommended by the European Pharmacopoeia to assess cellular substrates safety. Regarding the *in vivo* test, two different animal models are used: rat and mouse. In particular, Van Steenis and van Wezel (1981) showed that anti-thymocyte globulin (ATG)-treated new-born rats developed tumours at the inoculation site and metastases, demonstrating that they were more sensitive than nude mice. In addition, the results of another study on athymic nude mice, suggested a possible correlation between the chromosome abnormalities of cell lines and their tumorigenic ability (Zhang et al. 2004).

Concerning our research, different methodologies were used to assess the tumorigenic potential of Vero cell lines at different passages, cultivated on different media and of TCs, with the aim of investigating the safety of this biological substrate commonly applied in vaccine manufacture. Moreover, after the assessment of the tumorigenic phenotype, karyotyping and RNASeq experiments were carried out to search for biological alterations correlated to transformation.

Low- (from p127 to p139), high- (p194) passage Vero cells, as well as TCs, maintained in serum-supplemented and serum-free medium, were able to develop transformed colonies in the soft agar semi-solid medium with consistent timings and amounts, suggesting a common transformed genetic pattern. This result confirmed previous observation at the Cell Culture Centre of TC development in Vero cell cultures starting from different batches and passages.

306 In nude mice inoculated with p127 and p139 passages of Vero cells cultured with and without  
307 serum, no tumour was detected at the site of injection and cells were absorbed rapidly. These results  
308 are consistent with other studies that confirmed the absence of tumour formation at low Vero  
309 passages (Levenbook et al. 1984; Manohar et al. 2008).

310 The absence of correlation between *in vitro* and *in vivo* results contrasts what found in a previous  
311 study, in which different passage of cells (p146-p227, Furesz et al. 1989) were positive to both tests.  
312 One possible reason of this inconsistency could be the limited time length of the investigation,  
313 lasted 84 days (12 weeks). However, this period is beyond the limit of 69 days suggested by  
314 Manohar et al. as a lower limit by which tumour formation can be observed in adult nude mice  
315 (2008). Additionally, Furesz et al. reported tumour formation only after 21 days of observation  
316 (1987). These results suggest that the tumorigenic phenotype evolution is not correlated only to  
317 passage numbers, but to the target of genetic modification Vero cells have undergone during  
318 culturing.

319 Tumour-forming ability in nude mice may be associated to chromosome number variation. All  
320 samples of Vero cells showed a modal chromosome number (56, range 54-58) lower than the  
321 normal chromosome number of the AGMK ( $2n = 60$ ; Finelli et al. 1999). No other chromosomal  
322 abnormality was detected by cytogenetic analyses in the cells amplified serially, which were devoid  
323 of any malignant appearance.

324 Gene expression is influenced by cell immortalization and *in-vitro* culture (Ma et al. 2012;  
325 Dequéant et al. 2015; Garcia-Mesa et al. 2016). In particular, the number of *in-vitro* passages seems  
326 to influence gene regulation. Specifically, close passages induced differences in the expression of  
327 few genes (41 between p127 Vero and p134 Vero), while 4 to 6 fold increase in the number of  
328 differentially expressed gene are shown comparing p194 Vero with either p127 Vero or p134 Vero.  
329 If this pattern is common to long-term culture of all cell lines or specific to the Vero cells is to be  
330 investigated. Also it is presently unknown if gene expression gradually changes during passages or  
331 if a threshold exists beyond which cells start to change gene regulation.

332 However, the analysis of gene ontology and function of differentially expressed genes did not  
333 reveal changes that justify the tumorigenicity of p194 Vero cells observed in other investigations  
334 (Petricciani et al. 1987). Interestingly, Vero p194 showed a rather large cluster of downregulated  
335 genes and only few upregulated ones, when compared to the earlier passages; in addition GO of  
336 DEGs revealed no evidence of significant enrichment in cancer pathways.

337 In summary, we found no significant difference among low (p127 and p134) and high (p194) Vero  
338 passages in terms of transformation ability and karyotype. Differences in gene expression were  
339 detected, but metabolic pathways affected do not appear to be correlated to tumorigenesis. The  
340 choice of not testing *in vivo* p194 was undoubtedly a limitation, as the tumorigenicity of this  
341 passage at Cell Culture Center was inferred on the basis of external references. Joining our with  
342 existing results suggests that Vero are potentially tumorigenic cells, able to form TC even at low  
343 passages. The switch between these two states depends on random events and mechanisms that so  
344 far have not been identified but whose probability increases with the number of passages.

345 Therefore the use of Vero cells for biological production (such as *Poliovirus* vaccine manufacture)  
346 is suggested at the lowest possible available passage (Aubrit et al. 2015) to minimise risk. Such  
347 limitation strongly suggests to move towards already available alternative cell lines, such as FRhK-  
348 4 and 4647 lines in *Poliovirus* vaccine production (Dotti et al. 2017), as well as the so-called  
349 “designer” cell lines, as proposed by Brown and Mehtali (2010).

## 350 **References**

- 351 Anders S, Pyl PT, Huber W (2015) HTSeq--a Python framework to work with high-throughput  
352 sequencing data. *Bioinformatics*, 31(2):166-169.
- 353 Aubrit F, Perugi F, Léon A, Guéhenneux F, Champion-Arnaud P, Lahmar M, Schwamborn K  
354 (2015) Cell substrates for the production of viral vaccines. *Vaccine*, 33(44):5905-5912.
- 355 Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ (2011)  
356 Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a  
357 multicentre, double-blind, randomised, placebo-controlled trial. *Lancet*; 377(9767):751-759.

358 Barrett PN, Portsmouth D, Ehrlich HJ (2013) Vero cell culture-derived pandemic influenza  
359 vaccines: preclinical and clinical development. *Expert Rev Vaccines*, 12(4):395-413. Review.

360 Bioconductor- open source software for bioinformatics.  
361 <http://www.bioconductor.org/packages/release/bioc/vignettes/edgeR/inst/doc/edgeRUsersGuide.pdf>

362 Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence  
363 data. *Bioinformatics*, 30:2114-2120.

364 Brown SW, Mehtali M (2010) The Avian EB66(R) Cell Line, Application to Vaccines, and  
365 Therapeutic Protein Production. *PDA J Pharm Sci Technol* 64(5):419-25.

366 Cell substrates for the production of vaccines for human use. *European Pharmacopoeia* Ed. 08  
367 Chapter 5.2.3.

368 Chen T, Chen K (2009) Investigation and application progress of Vero cell serum-free culture.  
369 *International Journal of Biology* 1(2):41-47.

370 Chen A, Poh SL, Dietzsch C, Roethl E, Yan ML, Ng SK (2011) Serum-free microcarrier based  
371 production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.  
372 *BMC Biotechnol*. doi: 10.1186/1472-6750-11-81.

373 Contreras G, Bather R, Furesz J, Becker BC (1985) Activation of metastatic potential in African  
374 green monkey kidney cell lines by prolonged *in vitro* culture. *In vitro Cell Dev Biol* 21:649-652.

375 Dequéant ML, Fagegaltier D, Hu Y, Spirohn K, Simcox A, Hannon GJ, Perrimon N (2015)  
376 Discovery of progenitor cell signatures by time-series synexpression analysis during *Drosophila*  
377 embryonic cell immortalization. *Proc Natl Acad Sci U S A*. 112(42):12974-9. Erratum in: *Proc Natl*  
378 *Acad Sci U S A*. 112(46):E6408.

379 Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras  
380 TR (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, 29:15-21.

381 Dotti S, Lombardo T, Villa R, Cacciamali A, Zanotti C, Andreani NA, Cinotti S, Ferrari M (2017)  
382 Transformation and tumorigenicity testing of simian cell lines and evaluation of *Poliovirus*  
383 replication. *PlosOne*, 12(1):e0169391.

384 Finaz C, Dubois MF, Cochet C, Vignal M, de Grouchy J (1976) Le caryotype du Chercopithèque  
385 (*Cercopithecus Aethiops*) marquage et nomenclature. *Ann Genet* 19:213-216.

386 Finelli P, Stanyon R, Plesker R, Ferguson-Smith MA, O'Brien PC, Wienberg J (1999) Reciprocal  
387 chromosome painting shows that the great difference in diploid number between human and  
388 African green monkey is mostly due to non-Robertsonian fissions. *Mamm Genome* 10:713-718.

389 Frazatti-Gallina NM, Mourão-Fuches RM, Paoli RL, Silva ML, Miyaki C, Valentini EJ, Raw I,  
390 Higashi HG (2004) Vero-cell rabies vaccine produced using serum-free medium. *Vaccine* 23:511-  
391 517.

392 Furesz J, Fanok A, Contreras G, Becker B (1989) Tumorigenicity testing of various cell substrates  
393 for production of biological. *Dev Biol Stand* 70:233-243.

394 Garcia-Mesa Y, Jay TR, Checkley MA, Luttge B, Dobrowolski C, Valadkhan S, Landreth GE, Karn  
395 J, Alvarez-Carbonell D (2016) Immortalization of primary microglia: a new platform to study HIV  
396 regulation in the central nervous system. *J Neurovirol* PubMed PMID: 27873219.

397 Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG (1996) African green monkey  
398 kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. *J Virol.*  
399 Aug 70(8):5519-5524.

400 Hoff H, Belletti B, Zhang H, Sell C (2004) The Transformed Phenotype. Book chapter in *Cell*  
401 *Cycle Control and Dysregulation Protocols: Cyclins, Cyclin-Dependent Kinases, and Other Factors.*  
402 Ed. Giordano A and Romano G, Humana Press, Totowa, NJ, pp 95-104.

403 Johnson JB, Noguchi PD, Browne WC, Petricciani JC (1981) Tumorigenicity of continuous  
404 monkey cell lines in *in vivo* and *in vitro* systems. *Dev Biol Stand* 50:27-35.

405 Levenbook IS, Petricciani JC, Elisberg BL (1984) Tumorigenicity of Vero cells. *J Biol Stand*  
406 12:391-398.

407 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R  
408 (2009) The Sequence Alignment/Map format and SAMtools. *Bioinformatics*, 25:2078-2079.

409 Ma L, Nie L, Liu J, Zhang B, Song S, Sun M, Yang J, Yang Y, Fang X, Hu S, Zhao Y, Yu J (2012)  
410 An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial  
411 cells. *Genomics Proteomics Bioinformatics* 10(6):326-335.

412 Macpherson I, Montagnier L (1964) Agar suspension culture for the selective assay of cells  
413 transformed by polyoma virus. *Virol* 23:291-294.



414 Manohar M, Orrison B, Peden K, Lewis AM Jr (2008) Assessing the tumorigenic phenotype of  
 415 VERO cells in adult and new-born nude mice. *Biologicals* 36:65-72.

416 Montagnon BJ (1989) Polio and rabies vaccines produced in continuous cell lines: a reality for Vero  
 417 cell line. *Dev Biol Stand* 70:27-47.

418 Petricciani JC, Levenbook IS, Wierenga DE, Qi Y (1987). Early passage primate cell immortality is  
 419 independent of tumorigenicity. *In vitro Cell & Dev Biology* 23:523-526.

420 Reimand J, Arak T, Adler, P, Kolberg L, Reisberg S, Peterson H, Vilo J (2016) g:Profiler -- a web  
 421 server for functional interpretation of gene lists (2016 update). *Nucleic Acids Research*; doi:  
 422 10.1093/nar/gkw199.

423 Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false  
 424 discovery rate controlling procedures. *Bioinformatics* 19:368–375.

425 Rhim JS, Schell K, Creasy B, Case W (1969) Biological characteristics and viral susceptibility of an  
 426 African green monkey kidney cell line (Vero). *Proc Soc Exp Biol Med* 132(2):670-678.

427 Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a Bioconductor package for differential  
 428 expression analysis of digital gene expression data. *Bioinformatics* 26(1):139-140.

429 Russell WMS, Burch RL (1959) *The Principles of Humane Experimental Technique*. London:  
 430 Methuen and Co. Ltd.

431 Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Müller (2011) Safety profile of the  
 432 Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®). *Vaccine*. 29(47):8669-  
 433 8676.

434 Sheets R (2000) Food and Drug Administration History and characterization of the Vero cell line. A  
 435 report prepared by CDR Rebecca Sheets, Ph. D., USPHS. CBER/OVRR/DVRPA/VVB for the  
 436 Vaccines and Related Biological Products Advisory Committee Meeting to be held on May 12,  
 437 2000. Available at <http://www.fda.gov/ohrms/dockets/AC/00/backgrd/3616b1a.pdf>.

438 Swanson SK, Mento SJ, Weeks-Levy C, Brock BD, Kowal KJ, Wallace RE, Ritchey MB, Cano FR  
 439 (1988) Characterization of Vero cells. *J Biol Stand* 16:311-320.

440 Teferedegne B, Macauley J, Foseh G, Dragunsky E, Chumakov K, Murata H, Peden K, Lewis AM  
 441 Jr (2014) MicroRNAs as potential biomarkers for VERO cell tumorigenicity. Vaccine,  
 442 32(37):4799-4805.

443 TTSeq: Analysing high throughput-sequencing data with Python. [http://www-huber.embl.de/users/](http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html)  
 444 [anders/HTSeq/doc/overview.html](http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html).

445 US FDA, CBER, Vaccines and related biological products advisory committee meeting,  
 446 Wednesday 16 May 2001 <http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3616b1a.pdf>.

447 Van Steenis G, van Wezel AL (1981) Use of the ATG-treated new-born rat for *in vivo*  
 448 tumorigenicity testing of cell substrates. Dev Biol Stand 50:37-46.

449 WHO Expert Committee on Biological Standardization. Sixty-first report. WHO Technical Report  
 450 Series, No. 978, 2013 Annex 3. Recommendations for the evaluation of animal cell cultures as  
 451 substrates for the manufacture of biological medicinal products and for the characterization of cell  
 452 banks. Available at: [http://www.who.int/biologicals/expert\\_committee/TRS\\_978\\_61st\\_report.pdf](http://www.who.int/biologicals/expert_committee/TRS_978_61st_report.pdf).

453 Yasumura Y, Kawakita Y (1963) Study of SV40 in tissue culture. Nippon Rinsho 21:1201–1205.

454 Zhang DL, Ji L, Li LJ, Huang GS (2004) Systematically experimental investigation on  
 455 carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice *in vivo*  
 456 used for viral vaccine manufacture. Acta Genetica Sinica 31:647-660.

457 Zhang DL, Liu SG, Yan LF, Li LJ, Huang GS, Fang FD, Xia GT, He XY, Gao BX, Bai XH, Wang  
 458 W, Ding PG (2001) Carcinogenesis or tumorigenicity testing of animal cell lines for vaccine  
 459 preparation by colony formation on soft agar and by agglutination under plant lectins. Cell Biol Int  
 460 25:997-1002.

## 461 **Figure legend**

### 462 **Fig. 1** *In vitro* transformation assay

463 Transformed colonies produced in soft-agar by Vero (p130) and HEp-2 cell lines (positive control)  
 464 are shown respectively in figure 1A e 1B, while results from AGMK (one of the two negative  
 465 controls) are reported in figure 1C.

### 466 **Fig. 2** Metaphase of p127 Vero

467 The arrows shows two of the rearranged chromosomes.

468 **Fig. 3** Differential expressed genes in pairwise comparisons among the three Vero lines tested.  
469 Venn diagrams report graphically the number of DEGs in single and multiple comparisons of the  
470 indicated Vero passages. Intersections define groups of DEGs resulted common to two or more  
471 comparisons.

472 **Fig. 4** Heat map reporting log fold change of the DEGs identified in p127 Vero- p134 Vero and  
473 p134 Vero-p194 Vero comparisons

474 Log fold-changes are depicted with a colour scale where red represents the up-regulated genes and  
475 green represents the down-regulated ones. Up- and down-regulation is referred to the first term of  
476 the comparison reported in the label at the bottom of the figure. Rows and columns are sorted on the  
477 basis of cluster analysis of gene expression similarities. The heat map was generated in R.

478 **Fig. S1:** Graphical representation of the experimental design and major results of the study. Dots in  
479 the *in vitro* section means positivity to the test. The red circle in the *in vivo* experiment means  
480 tumour formation after inoculum of the cell line in nude mice.

481 **Table legend**


482 **Tab. 1:** Summary of the main results of the study.

483 **Tab. S1:** Log fold-change of DEGs in pairwise comparisons. the first column reports feature IDs  
484 obtained in the RNA-seq experiment. Columns 2, 3 and 4 show log fold-change values of each  
485 pairwise comparison. A positive value means higher expression in the first term of the comparison;  
486 on the contrary, a negative value means higher expression in the second term of the comparison.


Figure 1

[Click here to download Figure Fig1.eps.eps](#)





## Vero p134 vs Vero p194




Vero p127 vs Vero p134


Vero p127 vs Vero p194

Figure 4

[Click here to download Figure Fig4.eps.eps](#) 










p139 Vero cells

Vero-transformed  
colonies (TCs)

with serum cultures

serum-free cultures





	<i>In vitro</i> transformation <sup>a</sup>	<i>In vivo</i> tumorigenicity	Karyotyping <sup>a,b</sup>	RNA-seq
p127 Vero	+	-	56	No enrichment in genes involved in tumorigenesis
p134 Vero	+	-	56	
p194 Vero	+	+*	56	
TCs	+	-	56	NP
p3 AGMK	-	-	60	NP
Hep-2	+	+	NP	NP
MRC-5	-	-	NP	NP

<sup>a</sup> *in vitro* transformation and karyotyping were performed on cells from p127 to p139. For sake of simplicity, Table 1 reports only data of lines that undergo also other steps of the investigation.

\* result based on Petricciani et al. 1987.

<sup>b</sup> table reports the observed modal chromosome number based on the observation of 20 metastases.

NP = not performed.



feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
ENSP00000324127_1	2,619274682	-0,610573139	-3,230368426
ENSP00000356832_1	-0,551804995	2,744371753	3,296897597
JK123643.1_1	-1,062622151	2,840022258	3,904691719
ENSP00000339820_1	1,457722446	-2,533940122	-3,99387525
ENSP00000422591_1	1,155605447	-2,483506176	-3,640560211
ENSP00000343877_1	0,800559522	-2,307131495	-3,108510429
ENSP00000251127_1	2,125696429	-2,312850716	-4,443108734
ENSP00000238682_1	-0,601238224	2,486957226	3,089182109
ENSP00000353582_1	2,856619736	-0,194009849	-3,051789143
ENSP00000310721_1	1,060947919	-2,531315827	-3,594915025
ENSP00000451438_1	1,444405038	-2,26859334	-3,717191588
ENSP00000256759_1	2,356003056	-1,86481169	-4,229721337
ENSP00000256925_1	0,716978005	-2,616474902	-3,336976958
JK088891.1_1	-0,858726962	2,654161685	3,51743801
ENSP00000230882_1	1,042719413	-2,62662004	-3,675157582
ENSP00000244050_1	-2,010398843	1,38797553	3,402757817
ENSP00000427888_1	-1,367970823	2,101608655	3,475282134
ENSP00000347689_1	0,858773411	-2,408940105	-3,273930967
ENSP00000265087_1	-0,353948702	2,650331069	3,008998656
ENSP00000217086_1	1,953477133	-2,015937807	-3,984711163
ENSP00000361636_1	-2,138407736	1,31669109	3,465201058
JK104268.1_1	-0,707669608	2,747081499	3,465201058
ENSP00000301305_1	-0,357425634	2,733030287	3,097296877
JK092877.1_1	-1,63702704	6,268981357	8,39443008
JK090900.1_1	1,552855101	-2,612573526	-4,18600494
ENSP00000401907_1	2,63583999	-1,00059891	-3,648356854
ENSP00000311609_1	-1,034070979	2,457395251	3,503920995
ENSP00000359621_1	0,76403787	-2,28133476	-3,052998209
ENSP00000308032_1	2,098829101	-2,318153348	-4,446992507
ENSP00000345008_1	1,747806943	-1,535984254	-3,293699076
ENSP00000451131_1	-0,601069854	2,587317905	3,198625638
ENSP00000449124_1	-1,788712835	5,693342571	7,969638385
ENSP00000256186_1	2,945697051	-0,563149358	-3,523436415
ENSP00000261383_1	-0,90036024	6,488698754	7,876912621
ENSP00000298943_1	-1,120168597	6,268981357	7,876912621
ENSP00000329137_1	-0,702366727	2,923441982	3,646477855
ENSP00000444171_1	1,157714226	-2,251305356	-3,424178951
ENSP00000266682_1	2,63583999	-0,530852125	-3,178161747
ENSP00000343339_1	-2,619067033	0,680652706	3,314088469
JK094060.1_1	-2,278311661	0,77638802	3,066111892
ENSP00000318119_1	-1,603218048	1,662065145	3,280243216
JK117113.1_1	-2,890636145	1,056019403	3,97606226
ENSP00000375847_1	-0,940343322	2,081489799	3,033783535
JK114877.1_1	-1,058101239	1,930739851	3,000714117
ENSP00000279168_1	-2,109080656	1,08642636	3,210073333
ENSP00000265165_1	1,643620071	-1,385852613	-3,041056528
ENSP00000265131_1	2,463387293	-0,764130648	-3,241878669
JK122975.1_1	-0,917834535	2,240778191	3,173665605
ENSP00000353198_1	-0,802890875	2,636214623	3,459475153
ENSP00000340943_1	2,014504239	-2,589510109	-4,660583434
ENSP00000270172_1	-1,071545656	3,494563012	4,625303798
ENSP00000365105_1	-1,472182758	2,344745534	3,847272646
ENSP00000303208_1	-1,997112147	1,08642636	3,097972175
ENSP00000349022_1	-2,281802391	1,076089138	3,37731403

feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
ENSP00000299882_1	-1,251684267	5,693342571	7,431683718
ENSP00000317027_1	1,733668776	-1,372189202	-3,120305859
ENSP00000252723_1	-2,102208591	1,622630781	3,754546883
ENSP00000357301_1	-0,541242796	3,182756266	3,754546883
ENSP00000368477_1	-0,389345802	6,488698754	7,364967387
ENSP00000331065_1	-0,858796027	3,494563012	4,412194339
ENSP00000387278_1	-0,319548745	6,488698754	7,295015584
ENSP00000458307_1	-3,036675243	3,774650585	7,295015584
JK105864.1_1	-0,798781575	6,009683671	7,295015584
ENSP00000353142_1	-1,696123147	1,481862791	3,197464018
ENSP00000375259_1	-1,545043532	2,028404435	3,603225567
JK125686.1_1	-1,071545656	2,057501577	3,148766038
ENSP00000253354_1	0	-6,730042384	-7,216713304
ENSP00000368102_1	5,336805398	-1,442473467	-7,216713304
ENSP00000257860_1	-2,886053168	3,774650585	7,144032866
ENSP00000444948_1	-2,886053168	3,774650585	7,144032866
ENSP00000268459_1	-1,280651129	1,798203891	3,098366666
ENSP00000412130_1	-2,158417484	1,946539195	4,162056544
ENSP00000439182_1	-1,721408072	1,622630781	3,373084953
ENSP00000339767_1	-0,479958914	6,009683671	6,975382319
ENSP00000370770_1	-6,539379833	0	6,975382319
ENSP00000417710_1	-1,769797766	4,72095754	6,975382319
ENSP00000312457_1	2,348618007	-0,711464499	-3,078735886
JK125441.1_1	2,014504239	-2,086371899	-4,156349512
ENSP00000306275_1	0	-6,469723486	-6,955617397
JK116968.1_1	3,82152725	-2,695072901	-6,955617397
ENSP00000350976_1	-6,44730409	0	6,883037048
ENSP00000297161_1	1,125520326	-2,229534483	-3,384234719
ENSP00000205890_1	-0,868578633	2,344745534	3,242601648
ENSP00000261275_1	2,014504239	-2,009084844	-4,078857564
JK107001.1_1	-1,937998351	1,946539195	3,941122022
JK118361.1_1	-1,37077502	2,513150573	3,941122022
ENSP00000274532_1	3,82152725	-2,596699454	-6,856911712
ENSP00000445247_1	-2,527421587	3,774650585	6,784374174
JK110883.1_1	-1,57936677	4,72095754	6,784374174
JK124819.1_1	-0,128844757	3,014396168	3,172649845
JK113872.1_1	-6,625930005	-2,774418344	3,859259746
ENSP00000289388_1	-2,421867208	3,774650585	6,678465391
ENSP00000379684_1	0,485963278	6,679334305	6,678465391
ENSP00000396755_1	-2,421867208	3,774650585	6,678465391
JK101839.1_1	-0,90658906	5,287568917	6,678465391
ENSP00000064724_1	-1,448050845	1,622630781	3,099132689
ENSP00000361935_1	3,563767563	-0,292833817	-3,91014443
ENSP00000327538_1	-0,479958914	3,235265327	3,772471476
ENSP00000351805_1	-1,202574435	2,513150573	3,772471476
ENSP00000364348_1	-0,000726084	3,71428041	3,772471476
ENSP00000411145_1	0,189977903	3,90491596	3,772471476
JK119441.1_1	-0,220534441	3,494563012	3,772471476
ENSP00000287713_1	2,674783651	-0,461061027	-3,163228536
ENSP00000300961_1	-1,937998351	1,056019403	3,021667127
JK100196.1_1	-0,964689576	2,028404435	3,021667127
JK121760.1_1	-1,937998351	1,056019403	3,021667127
JK107401.1_1	0	-6,151859094	-6,636592175
ENSP00000349401_1	0,599854487	6,679334305	6,564161444

feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
JK091637.1_1	-2,307975999	3,774650585	6,564161444
ENSP00000223364_1	-2,625776839	1,000232241	3,680126205
JK099475.1_1	-6,44730409	-2,774418344	3,680126205
ENSP00000278314_1	0,532809253	6,488698754	6,440015926
ENSP00000326031_1	-2,184317246	3,774650585	6,440015926
JK122419.1_1	-0,669039098	5,287568917	6,440015926
ENSP00000219070_1	2,58172757	-1,083781122	-3,719055972
ENSP00000315295_1	1,066449422	-2,596699454	-3,719055972
ENSP00000360269_1	1,066449422	-2,596699454	-3,719055972
ENSP00000359512_1	-1,012143439	2,513150573	3,581463331
ENSP00000421258_1	-2,527421587	1,000232241	3,581463331
JK097403.1_1	-1,57936677	1,946539195	3,581463331
ENSP00000299727_1	1,066449422	-2,491124118	-3,613097854
ENSP00000344173_1	1,066449422	-2,491124118	-3,613097854
ENSP00000277517_1	-2,421867208	1,000232241	3,475554547
ENSP00000300079_1	-2,421867208	1,000232241	3,475554547
ENSP00000323155_1	-1,473812391	1,946539195	3,475554547
ENSP00000473361_1	-2,421867208	1,000232241	3,475554547
JK100278.1_1	-0,500503616	2,918924227	3,475554547
ENSP00000343782_1	0	-5,892876977	-6,376454814
ENSP00000356771_1	3,82152725	-2,118226391	-6,376454814
JK094464.1_1	4,769582067	-1,171919437	-6,376454814
ENSP00000158762_1	-0,533778926	5,287568917	6,304173084
ENSP00000252085_1	-2,049057074	3,774650585	6,304173084
ENSP00000363081_1	0,448261067	6,268981357	6,304173084
ENSP00000365173_1	-2,049057074	3,774650585	6,304173084
ENSP00000406318_1	0,448261067	6,268981357	6,304173084
JK098797.1_1	-0,533778926	5,287568917	6,304173084
ENSP00000263326_1	1,066449422	-2,377208509	-3,498736436
ENSP00000319744_1	-0,792697851	2,513150573	3,361250601
ENSP00000396622_1	-2,307975999	1,000232241	3,361250601
ENSP00000439601_1	-2,307975999	1,000232241	3,361250601
JK095107.1_1	-6,129503249	-2,774418344	3,361250601
JK106362.1_1	-1,359921182	1,946539195	3,361250601
JK106489.1_1	-2,307975999	1,000232241	3,361250601
JK109650.1_1	-2,307975999	1,000232241	3,361250601
JK113424.1_1	-0,792697851	2,513150573	3,361250601
ENSP00000269703_1	0	-5,743569099	-6,226379856
ENSP00000339256_1	4,769582067	-1,022611559	-6,226379856
ENSP00000421169_1	0	-5,743569099	-6,226379856
ENSP00000263266_1	-5,721318377	0	6,154197121
ENSP00000288065_1	-5,721318377	0	6,154197121
ENSP00000359904_1	-1,899791127	3,774650585	6,154197121
ENSP00000377971_1	-0,95173631	4,72095754	6,154197121
JK108999.1_1	-1,899791127	3,774650585	6,154197121
ENSP00000324248_1	-0,181910154	8,599408654	8,789084031
ENSP00000353427_1	0,71421195	5,084041388	4,370184695
JK092522.1_1	0,367485659	5,237883461	4,872112057
ENSP00000368759_1	0,689440424	5,368665504	4,681425579
ENSP00000227756_1	0,552701821	3,786515271	3,234266241
ENSP00000358590_1	1,653658391	6,0919394	4,445735231
ENSP00000264381_1	2,130470642	11,68243599	10,04205614
ENSP00000303153_1	0,304128115	-3,463999919	-3,768493664
ENSP00000349677_1	0,054360726	-3,484326888	-3,539031379

feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
ENSP00000338217_1	1,191306037	7,318383043	6,149402417
ENSP00000274364_1	0,117793789	3,652874361	3,536050196
ENSP00000285013_1	1,625542932	11,28047863	10,14505526
ENSP00000245479_1	1,565281705	4,818160459	3,256862291
ENSP00000453969_1	0,457703678	3,488654187	3,031753663
ENSP00000294829_1	-0,015677254	5,314613765	5,337880969
ENSP00000225688_1	0,642624312	4,380592676	3,741093582
ENSP00000344479_1	0,922045685	4,3549569	3,436136349
ENSP00000420194_1	0,290320978	4,950615121	4,666434216
ENSP00000463533_1	-1,122613762	-4,914719	-3,794097732
JK100938.1_1	-0,065535489	3,336762118	3,403557144
ENSP00000262352_1	-0,006936532	3,568509701	3,577201903
ENSP00000363512_1	0,778781547	4,068080797	3,292656382
ENSP00000361917_1	0,631291635	4,294327128	3,667380681
ENSP00000365651_1	0,804908223	3,914597967	3,112835241
ENSP00000377003_1	0,506681443	4,664149	4,164831046
ENSP00000289547_1	0,103512235	3,160259547	3,058106196
ENSP00000222219_1	0,17726651	7,521275207	7,40574109
ENSP00000354794_1	-0,198641815	-3,890445652	-3,695132826
JK111776.1_1	-0,730775564	3,872267778	4,608644528
ENSP00000312368_1	1,020220817	9,666964492	9,136362402
ENSP00000359778_1	2,599899753	-3,319460074	-5,935305493
ENSP00000312070_1	1,538301839	4,732925929	3,210073333
ENSP00000332530_1	0,516177542	3,923066384	3,414835272
ENSP00000261180_1	-2,755077828	-9,406570964	-6,75869621
ENSP00000321049_1	1,076214207	4,365262962	3,301560636
ENSP00000310878_1	-1,073506427	-5,668703555	-4,611035031
ENSP00000343617_1	0,485698558	4,274266183	3,801437579
ENSP00000393198_1	1,254115287	4,242612166	3,000714117
ENSP00000405218_1	0,874803004	9,025511724	8,639917969
JK123722.1_1	-0,587833907	8,953503899	10,03133995
ENSP00000399985_1	-0,90658906	-4,106529587	-3,205608776
ENSP00000369129_1	0,29525929	-3,178480499	-3,47879616
ENSP00000473091_1	0,886239757	8,575865029	8,178313786
JK117245.1_1	1,631667636	8,575865029	7,431683718
ENSP00000361788_1	0,799159501	4,315606014	3,537208263
JK093232.1_1	-0,003098682	3,023228795	3,03248401
ENSP00000296327_1	0,234409912	3,3673204	3,141759979
ENSP00000442046_1	5,336805398	-3,636905417	-9,414212059
ENSP00000264072_1	-1,073506427	-4,797974138	-3,739810357
ENSP00000386393_1	0,585638827	8,313586582	8,216656867
ENSP00000282326_1	0,316319891	8,25488182	8,427499498
JK093866.1_1	0,104105852	8,25488182	8,639917969
ENSP00000320604_1	1,536444446	5,41926826	3,941122022
ENSP00000321962_1	-0,384512979	-3,491001357	-3,114019729
JK093908.1_1	-0,048930561	5,355361883	5,46495195
ENSP00000281821_1	0,881604714	4,984907225	4,162056544
ENSP00000337555_1	-0,274097662	4,984907225	5,319478398
JK095209.1_1	0,631962847	7,759325569	7,615105183
ENSP00000216733_1	0,603380389	4,897860488	4,353607229
ENSP00000384193_1	1,47914882	4,897860488	3,475554547
ENSP00000379353_1	-0,533888103	4,007340696	4,572910861
ENSP00000272252_1	0,190875185	4,805222523	4,674001778
ENSP00000349678_1	1,003959169	4,805222523	3,859259746

feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
ENSP00000279441_1	-0,334001583	3,547845789	3,902901476
JK099477.1_1	0,411710778	4,70622545	4,353607229
JK099942.1_1	0,904943663	4,70622545	3,859259746
ENSP00000290552_1	0,746017424	3,815705657	3,099132689
ENSP00000344674_1	-1,014081553	3,460799052	4,496372873
ENSP00000472867_1	-0,093062449	3,460799052	3,574558612
ENSP00000310880_1	-0,752437392	7,480643794	8,722179193
ENSP00000346990_1	0,353232249	7,480643794	7,615105183
ENSP00000351280_1	0,904943663	7,480643794	7,062170589
JK122602.1_1	0,429983315	7,374349802	7,431683718
ENSP00000315602_1	-4,190035741	-7,25636939	-3,135050294
ENSP00000379256_1	1,066449422	-3,866519973	-4,991823929
ENSP00000423390_1	-3,644061741	-7,141678295	-3,575839244
ENSP00000293725_1	-0,59664408	3,709411665	4,337462117
ENSP00000269080_1	-0,630529359	7,134921762	8,254007216
JK114322.1_1	0,737772279	7,134921762	6,883037048
ENSP00000349494_1	0,91906066	6,99844435	6,564161444
ENSP00000330523_1	-0,030228358	6,847694402	7,364967387
ENSP00000361761_1	0,654376735	6,847694402	6,678465391
JK123883.1_1	-0,030228358	6,847694402	7,364967387
ENSP00000348602_1	-0,160442277	4,073276058	4,292539848
ENSP00000360425_1	0,35839136	4,073276058	3,772471476
JK118565.1_1	-0,030228358	4,073276058	4,162056544
ENSP00000296575_1	0,177465509	-3,587959848	-3,79719036
ENSP00000334128_1	0	-6,880685804	-7,36774617
ENSP00000395461_1	0,126862899	3,469983625	3,373084953
JK103161.1_1	2,191436022	4,857734403	2,666509416
JK103279.1_1	2,005712511	4,703728106	2,698830058
JK091645.1_1	2,522419672	5,164893736	2,644113977
ENSP00000318057_1	2,666370904	4,829074794	2,163754616
ENSP00000245919_1	2,644377091	3,547294088	0,90293293
ENSP00000242480_1	2,497774299	4,027637687	1,53026096
ENSP00000363804_1	2,13852069	4,964637117	2,828322135
ENSP00000260356_1	1,637389662	3,127718939	1,490366263
JK094840.1_1	0,787952781	3,176915914	2,389149842
ENSP00000359629_1	-0,758979662	-3,104593117	-2,345689701
ENSP00000356954_1	1,651244365	3,53765141	1,886920773
ENSP00000360158_1	-1,6351237	-3,473423208	-1,83844798
ENSP00000358596_1	2,148068796	4,223098911	2,07682371
JK112968.1_1	2,437010443	3,979545319	1,543729093
ENSP00000274181_1	1,958861267	4,818018522	2,863558394
JK097840.1_1	1,994601817	3,125399663	1,131351315
JK112739.1_1	2,086300548	3,718485228	1,633703074
ENSP00000282701_1	0,239787954	3,183357261	2,944568674
ENSP00000308330_1	-2,617279258	-4,344491643	-1,728365222
ENSP00000445626_1	2,785401556	3,849636795	1,067108629

feature IDs	p134 vs p127	p194 vs p127	p194 vs p134
ENSP00000301599_1	1,400253782	3,854582882	2,459201487
ENSP00000245552_1	0,162332495	3,066110186	2,906235486
ENSP00000299308_1	-0,99991823	-3,236232338	-2,237545903
ENSP00000194155_1	1,421591194	3,406454525	1,988466113
ENSP00000221166_1	1,400683588	3,559445737	2,163409721
JK105828.1_1	2,055296271	4,223245572	2,177195073
ENSP00000216286_1	-1,591194153	-4,47001472	-2,882729627
ENSP00000261304_1	0,894584408	3,019916207	2,127969875
ENSP00000283309_1	1,188917879	4,050187454	2,871369672
ENSP00000264867_1	1,657010326	3,678611508	2,02762736
ENSP00000262018_1	-1,523411571	-3,111566748	-1,589164078
JK105906.1_1	2,257841797	3,226439068	0,97130293
JK099313.1_1	2,934227147	4,210248022	1,284749427
JK092041.1_1	2,706715584	3,389340536	0,685715776
ENSP00000288976_1	1,571957739	3,329318142	1,762468944
ENSP00000324173_1	2,934227147	3,383633474	0,452085535
ENSP00000296591_1	0,97157576	3,254045941	2,287623044
JK113163.1_1	2,713279445	5,89431977	3,237105083
ENSP00000379154_1	1,768040252	4,364385249	2,61556698
JK100497.1_1	2,656383512	4,811661249	2,181807346
ENSP00000454748_1	0,857824952	3,046042725	2,19514581
ENSP00000282030_1	0,493757109	3,138413787	2,653084662
ENSP00000467931_1	0,703720151	3,396632031	2,704712035
JK118831.1_1	-1,782357491	-3,328664066	-1,54924862
JK109094.1_1	1,764284619	3,851431503	2,10492557
ENSP00000340864_1	1,096613274	4,007340696	2,939804851
ENSP00000413163_1	0,722842408	3,145956732	2,434498678
ENSP00000464976_1	0,674219467	3,145956732	2,483196658
ENSP00000328358_1	-1,57936677	-3,474291898	-1,90004956
JK091546.1_1	1,536444446	3,02167894	1,493013297
ENSP00000416561_1	2,734855496	4,805222523	2,119404684
ENSP00000238018_1	1,624044678	3,914702731	2,317650187
ENSP00000378067_1	2,058018201	4,599931457	2,594492354
ENSP00000272520_1	-5,366540222	-7,362610433	-2,05327193
ENSP00000360315_1	0,575762649	3,152409358	2,591064047
JK115319.1_1	0,951401772	3,152409358	2,214673973
ENSP00000366477_1	-5,14996425	-7,200163253	-2,108598444
JK097110.1_1	1,682023687	6,99844435	5,797403198
ENSP00000261187_1	2,153530231	4,224026005	2,119404684
ENSP00000395323_1	2,858528168	4,224026005	1,406279482
ENSP00000331581_1	1,066386385	3,048117213	1,999016787
ENSP00000242729_1	1,531230971	6,847694402	5,797403198
JK095711.1_1	1,531230971	6,847694402	5,797403198
JK108564.1_1	1,747806943	6,847694402	5,579327767
JK116885.1_1	2,312594577	6,847694402	5,00937381
ENSP00000354723_1	-2,184317246	-3,481718804	-1,304224693
ENSP00000398131_1	-5,14996425	-6,807329438	-1,714877485